An article in the Nov. 10, 2003, issue of BioWorld Today reported Cytogen's recent $20.5 million stock sale as being "more money than we ever raised." The company has since said the transaction puts Cytogen on course to enter 2004 with its strongest financial position in more than a decade. Cytogen also would like to clarify that it remains cautiously optimistic for approval of Combidex, an ultra-small superparamagnetic iron oxide contrast agent for magnetic resonance imaging of lymph nodes, to which it has exclusive U.S. marketing rights from Advanced Magnetics Inc. Combidex received a priority review by the FDA and the agency issued an approvable letter in June 2000. It is Cytogen's policy not to comment on the ongoing regulatory status of Combidex, other than that Combidex is being reviewed by the medical imaging division of the FDA.
Editor's note: The changes have been made in BioWorld Online.